Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment

Oncotarget

Volumn 5, Issue 9, 2014, Pages 2344-2348

  Menendez, Javier A ^a,b   Quirantes Piné, Rosa ^c   Rodríguez Gallego, Esther ^d   Cufí, Sílvia ^a,b   Corominas Faja, Bruna ^a,b   Cuyàs, Elisabet ^a,b   Bosch Barrera, Joaquim ^a,b   Martin Castillo, Begoña ^a,b   Segura Carretero, Antonio ^c   Joven, Jorge ^d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

Biguanides; Cancer; Diabetes; Insulin; Metformin; PI3K; PIK3CA mutations

Indexed keywords

ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; METFORMIN; METHOTREXATE; ONCOBIGUANIDE DERIVATIVE; PHENFORMIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CARCINOGENESIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LOW DRUG DOSE; LUNG CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; RECTUM CANCER; SKIN CANCER; DIABETES MELLITUS, TYPE 2; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84901218390     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1965     Document Type: Article

References (10)

1. Nzila A, Okombo J, Becker RP, Chilengi R, Lang T, Niehues T. Anticancer agents against malaria: time to revisit? Trends Parasitol. 2010; 26:125-1299.
2. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330:1304-1305.
3. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2:896-917.
4. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B, Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012; 3:395-398.
5. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin-Castillo B, Menendez JA. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep. 2012; 2:964.
6. Corominas-Faja B, Quirantes-Piné R, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Martin-Castillo B, Micol V, Joven J, Segura-Carretero A, Menendez JA. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012; 4:480-498.
7. Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, Dorca J, Martínez S, López NB, Fernández SD, Cuyàs E, Visa J, Rodríguez-Gallego E, Quirantes-Piné R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget. 2013; 4:1484-95.
8. Pollak M. Potential applications for biguanides in oncology. J Clin Invest. 2013; 123:3693-3700.
9. Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila). 2013; 6:801-810.
10. Bailey CJ, Day C. Metformin: its botanical background. Pract Diab Int. 2004; 21: 115-117.